Circulating RANKL/OPG in polymyalgia rheumatica

Clinical and Experimental Rheumatology

Volumn 25, Issue 4, 2007, Pages 621-623

  Pulsatelli, Lia ^a   Dolzani, Paolo ^a,c   Silvestri, Tania ^a,c   Boiardi, Luigi ^b   Salvarani, Carlo ^b   Macchioni, Pierluigi ^b   Facchini, Andrea ^a,c   Meliconi, Riccardo ^a,c  

^a RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

^b S MARIA NUOVA HOSPITAL   (Italy)

^c UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Osteoprotegerin; Polymyalgia rheumatica; RANKL

Indexed keywords

CORTICOSTEROID; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN;

AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FOLLOW UP; HUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN FUNCTION; RHEUMATIC POLYMYALGIA;

EID: 34648834438     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. XING L, SCHWARZ EM, BOYCE BF: Osteoclast precursors, RANKL/RANK, and immunology. Immunol Rev 2005; 208: 19-29.
2. SALVARANI C, CANTINI F, BOIARDI L, HUNDER GG: Polymyalgia reumatica. Best Pract Res Clin Rheumatol 2004; 18: 705-22.
3. LIGTHART GJ, CORBERAND JX, FOURNIER C et al.: Admission criteria for immunogerontological studies in man: The SENIEUR protocol. Mech Ageing Dev 1984; 28: 47-55.
4. SCHETT G, HAYER S, ZWERINA J, REDLICH K, SMOLEN JS: Mechanisms of disease: The link between RANKL and arthritic bone disease. Nat Clin Pract Rheumatol 2005; 1: 47-54.
5. FONSECA JE, CORTEZ-DIAS N, FRANCISCO A et al.: Inflammatory cell infiltrate and RANKL/OPG expression in rheumatoid synovium: Comparison with other inflammatory arthropathies and correlation with outcome. Clin Exp Rheumatol 2005; 23: 185-92.
6. ZIOLKOWSKA M, KUROWSKA M, RADZIKOWSKA A et al.: High levels of osteoprotegerin and soluble receptor activator of nuclear factor kB ligand in serum of rheumatoid arthritis patients and their normalization after anti-tumor necrosis factor α treatment. Arthritis Rheum 2002; 46: 1744-53.
7. SKOUMAL M, KOLARZ G, HABERHAUER G, WOLOSZCZUK W, HAWA G, KLINGLER A: Osteoprotegerin and the receptor activator of NF-kappa B ligand in the serum and synovial fluid. A comparison of patients with longstanding rheumatoid arthritis and osteoarthritis. Rheumatol Int 2005; 26: 63-9.
8. FRANCK H, MEURER T, HOFBAUER LC: Evaluation of bone mineral density, hormones, biochemical markers of bone metabolism, and osteoprotegerin serum levels in patients with ankylosing spondylitis. J Rheumatol 2004; 31: 2236-41.
9. KIM HR, KIM HY, LEE SH: Elevated serum levels of soluble receptor activator of nuclear factors-kappa B ligand (sRANKL) and reduced bone mineral density in patients with ankylosing spondylitis (AS). Rheumatology 2006; 45: 1197-200.
10. DOLAN AL, MONIZ C, DASGUPTA B et al.: Effects of inflammation and treatment on bone turnover and bone mass in polymyalgia rheumatica. Arthritis Rheum 1997; 40: 2022-9.
11. BARNES TC, DAROSZEWSKA A, FRASER WD, BUCKNALL RC: Bone turnover in untreated polymyalgia rheumatica. Rheumatology 2004; 43: 486-90.
12. SALVARANI C, CANTINI F, NICCOLI L et al.: Acute-phase reactants and the risk of relapse/recurrence in polymyalgia rheumatica. A prospective follow-up study. Arthritis Rheum 2005; 53: 33-8.
13. KWAN TAT S, PADRINES M, THEOLEYRE S, HEYMANN D, FORTUN Y: IL-6, RANKL, TNF-alpha/IL-1: Interrelations in bone resorption pathophysiology. Cytokine Growth Factor Rev 2004; 15: 49-60.
14. MAKRYGIANNAKIS D, AF KLINT E, CATRINA SB et al.: Intraarticular corticosteroids decrease synovial RANKL expression in inflammatory arthritis. Arthritis Rheum 2006; 54: 1463-72.
15. MELICONI R, PULSATELLI L, DOLZANI P et al.: Vascular endothelial growth factor production in polymyalgia rheumatica. Arthritis Rheum 2000; 43: 2472-80.
16. MIN JK, KIM YM, KIM YM et al.: Vascular endothelial growth factor up-regulates expression of receptor activator of NF-kB (RANK) in endothelial cells: Concomitant increase of angiogenic responses to RANK ligand. J Biol Chem 2003; 278: 39548-57.
17. UDDHAMMAR AC: Von Willebrand factor in polymyalgia rhoumatica and giant cell arteritis. Clin Exp Rheumatol 2000; 18: S32-3.